ADAG:NASDAQ, Adagene Inc.
ADAG stock overview
Adagene Inc. (ADAG:NASDAQ) closed at $2.06 on October 16, 2026,
down 14.17% on the day.
The stock trades 57.5% below its 52-week high of $4.85
and 58.5% above its 52-week low of $1.30.
Over the past year, it gained 17.0%.
Adagene Inc. is part of the Health Care sector.
Key figures
- Price
- $2.06
- Day change
- -14.17%
- Volume
- 379,601
- Average volume
- 284,601
- Market cap
- 138M+
- 52-week range
- $1.30 – $4.85
- 50-day average
- $3.38
- 200-day average
- $3.38
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -24.82% |
-38.87% |
-43.09% |
-47.04% |
+17.05% |
Price action over the past year
In 252 trading sessions since October 16, 2025, ADAG closed higher on 117 days (46%).
Its best day was January 23, 2026 (+22.66%) and its worst was October 16, 2026 (-14.17%).
The stock moved 10% or more in a single session 23 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
ADAG news
-
Oct 16, 2026:
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
-
Oct 14, 2026:
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
-
Sep 22, 2026:
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
-
Sep 10, 2026:
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
-
Sep 10, 2026:
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody Technology
-
Sep 9, 2026:
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
-
Sep 9, 2026:
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates
-
Aug 20, 2026:
Adagene to Participate in Three Upcoming Investor Conferences
About Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Similar stocks
Find more stocks like ADAG with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.